Optus Pharmaceutical Co Ltd
KOSDAQ:131030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (4), the stock would be worth ₩4 262.64 (57% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.3 | ₩9 850 |
0%
|
| 3-Year Average | 4 | ₩4 262.64 |
-57%
|
| 5-Year Average | 3.5 | ₩3 700.78 |
-62%
|
| Industry Average | 13.9 | ₩14 739.33 |
+50%
|
| Country Average | 8.5 | ₩9 050.55 |
-8%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
165.4B KRW | 9.3 | 14.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 27.9 | 38.5 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
95.4B DKK | 12.6 | 23.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14B USD | 14.5 | 33.3 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.6 | 33.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.6 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
880.1B JPY | 23.5 | 49.8 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -81.4 | -36.4 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 14.6 | 22.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Optus Pharmaceutical Co Ltd
Glance View
OPTUS Pharmaceutical Co., Ltd. engages in the manufacture and sale of ophthalmic products. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 171 full-time employees. The company went IPO on 2010-12-03. The firm is primarily engaged in the manufacture and sale of eye drops and ophthalmic preparations such as dry eye treatment agents, conjunctivitis treatment agents, anti-inflammatory medication agents, glaucoma treatment agents and others.
